In situ aromatization enhances breast tumor estradiol levels and cellular proliferation
- PMID: 9500452
In situ aromatization enhances breast tumor estradiol levels and cellular proliferation
Abstract
The high concentrations of estradiol (E2) found in breast tumors of postmenopausal women could be the result of enhanced uptake from plasma or in situ aromatization of androgens to estrogens. To test the relative importance of these two mechanisms, a model system allowing precise distinction between each is required. Such a model was established using aromatase (A+)- and sham (A-)-transfected MCF-7 cells inoculated into ovariectomized (OVX) nude mice. To validate the model, the confounding effect of peripheral aromatization was first excluded experimentally. A- cells were inoculated into OVX mice as homoimplants (A- cells on both flanks) or heteroimplants (A- cells on one flank and A+ cells on the other), and growth of A- cells in response to exogenous aromatase substrate, androstenedione (delta4A), was evaluated. A- cells did not grow in either group during the 8 weeks of observation, indicating the lack of peripheral aromatization in OVX mice. The biological effects of in situ aromatization were then directly examined. We found that A+ cells in the heteroimplant group grew rapidly, and that the average weight of A+ tumor was 7.6-fold larger and tissue E2 concentration was 3-4-fold higher than A- tumors grown in the same animals. These results demonstrate that in situ aromatization rather than uptake can be a determinant of tumor E2 content and growth stimulation. An additional experiment was then designed to evaluate the relative importance of in situ synthesis versus uptake under conditions reflecting postmenopausal physiology. Groups of OVX mice bearing A+ cells received E2 Silastic implants to clamp plasma levels at 5, 7, 10, and 20 pg/ml or delta4A by injection. The highest tumor E2 concentration and growth rate were found in the group receiving delta4A. E2 delivered by Silastic implants always produced lower tissue E2 levels and tumor growth rates than resulted from in situ synthesis. These data provide direct evidence that under physiological conditions reflecting those in postmenopausal women, in situ aromatization in breast tumor makes a major contribution to tissue E2 content. As further validation that our experimental paradigm models the postmenopausal state, we studied OVX animals not given delta4A as substrate. A+ cells also grew under these conditions, and the aromatase inhibitor 4-hydroxyandrostenedione reduced both tumor E2 level and growth rate, providing additional evidence of the importance of in situ synthesis. These studies provide the first direct evidence that in situ synthesis of E2 in breast tumors, as opposed to peripheral aromatization and uptake from plasma, can enhance tissue E2 levels and stimulate tumor growth.
Similar articles
-
Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations.Carcinogenesis. 2006 Jun;27(6):1292-9. doi: 10.1093/carcin/bgi370. Epub 2006 Mar 14. Carcinogenesis. 2006. PMID: 16537557
-
A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene.Cancer Res. 1994 Oct 1;54(19):5092-5. Cancer Res. 1994. PMID: 7923123
-
Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.Clin Cancer Res. 2000 May;6(5):2028-36. Clin Cancer Res. 2000. PMID: 10815929
-
Aromatase in the normal breast and breast cancer.J Steroid Biochem Mol Biol. 1997 Apr;61(3-6):281-6. J Steroid Biochem Mol Biol. 1997. PMID: 9365202 Review.
-
Aromatase expression and its localization in human breast cancer.J Steroid Biochem Mol Biol. 1997 Apr;61(3-6):293-8. J Steroid Biochem Mol Biol. 1997. PMID: 9365204 Review.
Cited by 32 articles
-
Effects of anastrozole on Ki-67 antigen expression in the vaginal epithelium of female rats in persistent estrus.Clinics (Sao Paulo). 2020 Apr 3;75:e1643. doi: 10.6061/clinics/2020/e1643. eCollection 2020. Clinics (Sao Paulo). 2020. PMID: 32267395 Free PMC article.
-
Synthesis and Biological Evaluation of Genistein-IR783 Conjugate: Cancer Cell Targeted Delivery in MCF-7 for Superior Anti-Cancer Therapy.Molecules. 2019 Nov 14;24(22):4120. doi: 10.3390/molecules24224120. Molecules. 2019. PMID: 31739548 Free PMC article.
-
Effect of a tissue selective estrogen complex on breast cancer: Role of unique properties of conjugated equine estrogen.Int J Cancer. 2018 Sep 1;143(5):1259-1268. doi: 10.1002/ijc.31401. Epub 2018 Apr 16. Int J Cancer. 2018. PMID: 29577272 Free PMC article.
-
Steroidogenic enzyme expression in estrogen production in the goat gastrointestinal (GI) tract and the effect of castration.J Vet Med Sci. 2017 Jul 19;79(7):1253-1260. doi: 10.1292/jvms.17-0093. Epub 2017 Jun 2. J Vet Med Sci. 2017. PMID: 28579582 Free PMC article.
-
Effects of Combination of Estradiol with Selective Progesterone Receptor Modulators (SPRMs) on Human Breast Cancer Cells In Vitro and In Vivo.PLoS One. 2016 Mar 24;11(3):e0151182. doi: 10.1371/journal.pone.0151182. eCollection 2016. PLoS One. 2016. PMID: 27011208 Free PMC article.
Publication types
MeSH terms
Substances
Grant support
LinkOut - more resources
-
Full Text Sources
-
Other Literature Sources